BIO vs QGEN: Which Stock Is the Better Buy?
Bio-Rad Laboratories, Inc. and Qiagen N.V. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BIO vs QGEN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Bio-Rad Laboratories, Inc. (BIO) | Qiagen N.V. (QGEN) | |
|---|---|---|
| Market cap | $7.8B | $7.6B |
| Revenue (latest FY) | $2.58B | $2.09B |
| Net income (latest FY) | $759.90M | $424.88M |
| Revenue growth (5y CAGR) | 0.3% | -0.8% |
| Net margin | 29.4% | 20.3% |
| Return on equity | 10.2% | 11.2% |
| P/E ratio | 48.8 | 18.8 |
| Dividend yield | — | 0.9% |
| Profitable years (of last 10) | 7 | 4 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BIO vs QGEN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BIO's full financials → Open QGEN's full financials →More comparisons
Frequently asked questions
Which is bigger, BIO or QGEN?
Bio-Rad Laboratories, Inc. is larger by market capitalization — $7.8B versus $7.6B.
Which grows faster, BIO or QGEN?
Over the last five fiscal years, Bio-Rad Laboratories, Inc. grew revenue faster — 0.3%/yr versus -0.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
BIO fundamentals → · QGEN fundamentals → · All 1,500+ companies → · Free screener →